After-Hours Stock Movers: Sesen Bio,ATI Physical Therapy,WD-40 Co. and more

StreetInsider2021-10-20

After-Hours Stock Movers:

Sesen Bio (NASDAQ: SESN) 15.8% HIGHER; disclosed: On the morning of October 19, 2021, the US Food & Drug Administration (FDA) granted Sesen Bio, Inc.s (the Company) request for a Type A meeting to discuss the Chemistry, Manufacturing and Controls (CMC) issues raised in the FDAs Complete Response Letter (CRL) regarding the Companys Biologics License Application (BLA) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (the CMC Type A Meeting). The CMC Type A Meeting has been scheduled for October 29, 2021. During the CMC Type A Meeting, the Company intends to align on a path forward with the FDA related to the CMC issues raised in the CRL.

ATI Physical Therapy (NYSE: ATIP) 14.8% LOWER; Reports Prelim. Q3 Results, Lowers FY Revenue Guidance

WD-40 Co. (NASDAQ: WDFC) 8.9% LOWER; reported Q4 EPS of $0.61, $0.62 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $115.2 million versus the consensus estimate of $117.47 million.

Akero Therapeutics, Inc. (Nasdaq: AKRO) 4.1% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH).

Stride Inc. (NYSE: LRN) 2.4% HIGHER; reported Q1 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $400.2 million versus the consensus estimate of $359.48 million. Stride Inc. sees FY2022 revenue of $1.56-1.6 billion, versus the consensus of $1.47 billion.

United Airlines (NASDAQ: UAL) 2.2% HIGHER; reported Q3 EPS of ($1.02), $0.27 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.85 billion.

Netflix (NASDAQ: UAL) 1.2% LOWER;Netflix earnings, subscribers get a ‘Squid Game’ bounce, but forecast is tamer.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
18